埃索美拉唑的效果好吗？

In 2000, the oral formulation of esomeprazole (Nexium) was first launched in Sweden. In 2001, it was approved by the FDA for marketing in the United States. On July 30, 2020, AstraZeneca announced that the China National Medical Products Administration (NMPA) officially approved Nexium (esomeprazole sodium) injection for the prevention of stress ulcer bleeding in severe patients. Is esomeprazole effective?

The approval of this indication is based on the results of an independent, randomized, double-blind, parallel-group, multi-center Phase III clinical study conducted in China, which evaluated the efficacy and safety of intravenous esomeprazole (Nexium) 40 mg twice daily compared with continuous intravenous cimetidine in preventing upper gastrointestinal bleeding in Chinese critically ill patients.

The results of this randomized clinical trial with cimetidine as the positive control showed that during the treatment evaluation period, the rate of upper gastrointestinal bleeding in the esomeprazole (Nexium) group was lower than that in the cimetidine group (2.7% in the esomeprazole group and 4.6% in the cimetidine group). Esomeprazole (Nexium) 40 mg twice a day can effectively prevent upper gastrointestinal bleeding in severe patients. The safety profile of the esomeprazole (Nexium) group was similar to that of the cimetidine group. Among severe patients in China, it was generally well tolerated and no new safety issues were found.

In addition, esomeprazole (Nexium) has also been approved for 1. Gastroesophageal reflux disease (GERD). 2. Treatment of erosive reflux esophagitis. 3. Long-term maintenance treatment to prevent recurrence of cured esophagitis patients. 4. Symptom control of gastroesophageal reflux disease (GERD) combined with appropriate antimicrobial therapy to eradicate Helicobacter pylori. 5. Heal duodenal ulcers associated with Helicobacter pylori infection. 6. Prevent the recurrence of peptic ulcers related to Helicobacter pylori.